Drug intelligence / Profile preview

IMO-001

Development stage: Preclinical
Lead developer: Omic
Modality: Small Molecules

Overview

IMO-001 is a small molecule therapeutic candidate currently in the lead optimization stage of development by Omic Analytics. It is being investigated for the treatment of solid tumors within the field of immuno-oncology. The drug's mechanism of action is based on an undisclosed trispecific targeting strategy, intended to modulate multiple biological pathways simultaneously to enhance the immune system's ability to identify and eliminate tumor cells.

Beyond the preview

Go deeper on IMO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMO-001.

Explore the full profile